We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
1. Three agents with the potential to reach the market this year for Rett syndrome, Duchenne muscular dystrophy (DMD), and alopecia areata.
2. Other significant treatments expected in the next few years, including gene therapies and biosimilars.
3. Overviews of anticoagulants, the Food and Drug Administration (FDA)/National Institutes of Health (NIH) Critical Path for Rare Neurodegenerative Diseases partnership, and FDA Advisory Committee meetings.